人福醫藥(600079.SH)2019年業績扭虧為盈 淨利預達7.5-9.5億元
格隆匯1月10日丨人福醫藥(600079.SH)發佈2019年年度業績預告,預計2019年度實現歸屬於上市公司股東的淨利潤與上年同期(法定披露數據)相比,將實現扭虧為盈,實現歸屬於上市公司股東的淨利潤為7.5億元到9.5億元。歸屬於上市公司股東的扣除非經常性損益的淨利潤為4億元到6億元。
報告期內,公司集中資源發展既定專業細分領域,着力提升經營質量,核心醫藥主業保持穩定增長。公司計提資產減值損失同比大幅減少,影響報告期歸屬於上市公司股東的淨利潤同比增加約30億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.